½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, ¿¬·É´ëº°, À¯Åë ä³Îº°, Áö¿ªº°
Sprycel Market, By Application (Chronic myeloid leukemia, Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia), By Age Group, By Distribution Channel:, By Region
»óǰÄÚµå
:
1402589
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2023³â 12¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀå ±Ô¸ð´Â 2023³â 22¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤ ¹× ¿¹ÃøµÇ¸ç, 2030³â¿¡´Â 26¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 2.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ »ó¼¼ |
±âÁØ ¿¬µµ |
2022³â |
2023³â ½ÃÀå ±Ô¸ð |
22¾ï 2,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2018-2021³â |
¿¹Ãø ±â°£ |
2023-2030³â |
¿¹Ãø ±â°£ÀÇ CAGR |
2.80% |
2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø |
26¾ï 9,000¸¸ ´Þ·¯ |
±×¸² 1. ½ºÇÁ¶óÀ̼¿ ¼¼°è ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â

½ºÇÁ¶óÀ̼¿Àº ´Ù»çƼ´ÕÀÇ »óǰ¸íÀ¸·Î, ƯÁ¤ ¾Ï Ä¡·á¿¡ »ç¿ëµÇ´Â ¾à¹°ÀÔ´Ï´Ù. ´Ù»çƼ´ÕÀº Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)·Î ¾Ë·ÁÁø ¾à¹°±º¿¡ ¼ÓÇÕ´Ï´Ù. ´Ù»çƼ´ÕÀº ¾Ï¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀÌ¿¡ °ü¿©ÇÏ´Â È¿¼ÒÀΠƯÁ¤ Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ È°¼ºÀ» ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ½ºÇÁ¶óÀ̼¿Àº ÁַΠƯÁ¤ À¯ÇüÀÇ ¹éÇ÷º´, ƯÈ÷ Çʶóµ¨ÇÇ¾Æ ¿°»öüÀÇ Á¸À縦 Ư¡À¸·Î ÇÏ´Â ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(ALL)(Ph ALL)°ú ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á¿¡ »ç¿ëµÇ´Â Ç¥Àû Ä¡·áÁ¦ÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ÇÇ·Î, µÎÅë, ¸Þ½º²¨¿ò, ¼³»ç, ü¾× Àú·ù µîÀÌ ÀÖ½À´Ï´Ù. ÀϺΠȯÀÚ´Â Ç÷±¸ ¼ö °¨¼Ò, °£ ¼Õ»ó, ÃâÇ÷°ú °°Àº ´õ ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀ» °ü¸®ÇÏ°í ´ëóÇϱâ À§Çؼ´Â ÀÇ·áÁøÀÇ ¸é¹ÐÇÑ ¸ð´ÏÅ͸µÀÌ Áß¿äÇϸç, CML Áø´ÜÀ» ¹ÞÀº 12°³¿ù ÀÌ»óÀÇ ¼ºÀΰú ¼Ò¾Æ ¸ðµÎ¿¡°Ô Åõ¿©µË´Ï´Ù. ¶ÇÇÑ, Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ¶Ç´Â Ph ALL·Î ¾Ë·ÁÁø ±Þ¼º ¸²ÇÁ¸ð±¸ ¹éÇ÷º´ÀÇ Æ¯Á¤ ¾ÆÇüÀ» ¾Î°í ÀÖ´Â °°Àº ¿¬·É´ëÀÇ ¼ºÀΰú ¼Ò¾Æ¿¡°Ôµµ ó¹æµË´Ï´Ù. ¹éÇ÷º´Àº °ñ¼ö¿¡¼ ¹ß»ýÇÏ´Â ¹Ì¼º¼÷ ¹éÇ÷±¸°¡ °ü¿©ÇÏ´Â ¾Ç¼º Á¾¾çÀÔ´Ï´Ù. Á¤»óÀûÀÎ °úÁ¤¿¡¼ ÀÌ ¹éÇ÷±¸°¡ ¼º¼÷ÇÏ¸é °¨¿°°ú ½Î¿ì°í ½ÅüÀÇ ¸é¿ª ü°è¸¦ À¯ÁöÇϱâ À§ÇØ Ç÷·ù·Î µé¾î°¡°Ô µË´Ï´Ù.
½ÃÀå ¿ªÇÐ:
Ç¥Àû ÀûÀÀÁõ Áõ°¡, È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõ È®´ë, Çõ½ÅÀû ¹ßÀüÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ½ºÇÁ¶óÀ̼¿°ú °°Àº Ç¥ÀûÄ¡·áÁ¦ °³¹ßÀ» Æ÷ÇÔÇÑ ¾Ï ¿¬±¸ ¹× Ä¡·áÀÇ ¹ßÀüÀº ÀÇ·á Á¦°øÀÚ¿Í È¯ÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¼±ÅñÇÀ» È®´ëÇß½À´Ï´Ù. ÀÌ·Î ÀÎÇØ Ä¡·á ¿ä¹ýÀÇ ÀÏȯÀ¸·Î ½ºÇÁ¶óÀ̼¿ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
±×·¯³ª °·ÂÇÑ °æÀï, ƯÇã ¸¸·á, ±ÔÁ¦ ¹®Á¦, ºÎÀÛ¿ë, °¡°Ý Ã¥Á¤ ¹× »óȯÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ÀÌ º¸°í¼´Â 2022³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í CAGRÀ» Á¦½ÃÇÏ´Â ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù.
- ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µî ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ½ºÇÁ¶óÀ̼¿ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷:
Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ´ë»óÀÌ µÇ´Â ÀûÀÀÁõ º¸±Þ·ü Áõ°¡, À¯È¿¼º°ú ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ÀûÀÀÁõ È®´ë
- Ä¡¿ÇÑ °æÀï, ƯÇã ¸¸·á, ±ÔÁ¦»ó °úÁ¦
- Çõ½ÅÀûÀÎ Áøº¸
- ¿µÇ⠺м®
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° ¹ß¸Å/½ÂÀÎ
- PEST ºÐ¼®
- Porters ºÐ¼®
- ÀμöÇÕº´ ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19) ¿ªÇÐ
- °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
- °æÁ¦Àû ¿µÇâ
Á¦5Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿ëµµº°, 2018-2030³â
- ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML)
- Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º ¸²ÇÁ¾Æ±¸¼º ¹éÇ÷º´(Ph+ALL)
Á¦6Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, ¿¬·ÉÃþº°, 2018-2030³â
Á¦7Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â
- º´¿ø°ú Áø·á¼Ò
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
- Àü¹® ¾à±¹
Á¦8Àå ¼¼°èÀÇ ½ºÇÁ¶óÀ̼¿ ½ÃÀå, Áö¿ªº°, 2018-2030³â
- ºÏ¹Ì
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- ASEAN
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- GCC
- À̽º¶ó¿¤
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
Á¦9Àå °æÀï »óȲ
- Bristol-Myers Squibb(BMS)
Á¦10Àå ¼½¼Ç
ksm
¿µ¹® ¸ñÂ÷
The global Sprycel market size is estimated to be valued at US$ 2.22 billion in 2023 and is projected to reach US$ 2.69 billion by 2030, growing at a CAGR of 2.8% during the forecast period.
Report Coverage |
Report Details |
Base Year: |
2022 |
Market Size in 2023: |
US$ 2.22 Bn |
Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: |
2.80% |
2030 Value Projection: |
US$ 2.69 Bn |
Figure 1. Global Sprycel Market Share (%), by Region, 2023

Sprycel is the brand name for dasatinib, a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib works by inhibiting the activity of specific tyrosine kinases, which are enzymes involved in the growth and spread of cancer cells. Sprycel is a targeted medication primarily employed in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL), characterized by the presence of the Philadelphia chromosome (Ph+ ALL), and chronic myeloid leukemia (CML). Common side effects of Sprycel may include fatigue, headache, nausea, diarrhea, and fluid retention. Some patients may also experience more serious side effects, such as low blood cell counts, liver problems, and bleeding. Close monitoring by healthcare providers is important to manage and address any adverse effects. It is administered to both adults and children aged 12 months and older who are diagnosed with CML. Additionally, it is prescribed for adults and children in the same age group who are afflicted with a specific subtype of acute lymphoblastic leukemia known as Philadelphia chromosome-positive or Ph+ ALL. Leukemia is a malignancy involving immature white blood cells that develop within the bone marrow. In the normal course of events, as these white blood cells mature, they enter the bloodstream to combat infections and maintain the body's immune system.
Market Dynamics:
The increasing prevalence of targeted indications, their efficacy and safety profile, expanded indications, and innovative advancements are major factors expected to drive growth of the global sprycel market during the forecast period. Advancements in cancer research and treatment, including the development of targeted therapies like Sprycel, have expanded the options available to healthcare providers and patients. This has led to increased adoption of Sprycel as part of the treatment regimen.
However, strong competition, patent expiration, regulatory challenges, adverse effects, and pricing and reimbursement are expected to hamper the growth of the global Sprycel market over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global Sprycel market, and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Sprycel market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol-Myers Squibb (BMS)
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Sprycel market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Sprycel market
Detailed Segmentation:
- By Application:
- Chronic myeloid leukemia (CML)
- Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- By Age Group:
- Adult Patients
- Pediatric Patients
- By Distribution Channel:
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- By Company Profiles:
- Bristol-Myers Squibb (BMS)
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Global Sprycel, By Application
- Market Global Sprycel, By Age Group
- Market Global Sprycel, By Distribution Channel
- Market Global Sprycel, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of targeted indications, efficacy and safety profile, expanded indications
- Strong competition, patent expiration, regulatory challenges
- Innovative advancements
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Sprycel Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Sprycel Market, By Application, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Chronic myeloid leukemia (CML)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Sprycel Market, By Age Group, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
7. Global Sprycel Market, By Distribution Channel, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Sprycel Market, By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Bristol-Myers Squibb (BMS)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
°ü·ÃÀÚ·á